XML 18 R7.htm IDEA: XBRL DOCUMENT v3.22.4
Statements of Stockholders' Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Preferred Stock
Common Stock
Additional Paid-In Capital
Service Receivable
Accumulated other comprehensive loss
Accumulated Deficit
Balance (in shares) at Dec. 31, 2020   716 36,781        
Balance at Dec. 31, 2020 $ 128,158 $ 1 $ 4 $ 361,819 $ (2,171) $ 0 $ (231,495)
Increase (Decrease) in Stockholders' Equity              
Stock-based compensation 3,234     3,234      
Issuance of common stock upon exercise of warrants (in shares)     771        
Issuance of common stock upon exercise of warrants 1,263     1,263      
Sale of stock, shares issued (in shares) [1]     4,412        
Net proceeds [1] 34,187     34,187      
Preferred stock dividend payable on Series A Convertible Preferred Stock (24)           (24)
Unrealized loss on securities available-for-sale (142)         (142)  
Release of clinical trial funding commitment 2,032       2,032    
Net loss (28,291)           (28,291)
Balance (in shares) at Dec. 31, 2021   716 41,964        
Balance at Dec. 31, 2021 140,417 $ 1 $ 4 400,503 (139) (142) (259,810)
Increase (Decrease) in Stockholders' Equity              
Stock-based compensation 4,256     4,256      
Issuance of common stock upon exercise of warrants (in shares)     29        
Issuance of common stock upon exercise of warrants 75     75      
Issuance of common stock upon conversion of Convertible Preferred Stock (in shares)   (655) 2,684        
Issuance of common stock upon conversion of Convertible Preferred Stock (1) $ (1)          
Preferred stock dividend payable on Series A Convertible Preferred Stock             (24)
Unrealized loss on securities available-for-sale (253)         (253)  
Release of clinical trial funding commitment 139       139    
Cumulative preferred stock dividend adjustment [2] 414           414
Net loss (38,704)           (38,704)
Balance (in shares) at Dec. 31, 2022   61 44,677        
Balance at Dec. 31, 2022 $ 106,343 $ 0 $ 4 $ 404,834 $ 0 $ (395) $ (298,100)
[1] Net of expenses of $0.8 million.
[2] See Note 2 to the financial statements.